Details:
Tested Applications	WB
Target Information	RPB1 is a 220kDa sub-unit of RNA Polymerase II
Product Format	Ascites
Alternate Names	RNA polymerase II sub-unit 1, RPB1, DNA-directed RNA polymerase II subunit A, RNA-directed RNA polymerase II subunit RPB1, POLR2A, POLR2
Clone	12Y5
Host	Mouse
Isotype	IgM
Immunogen	Purified protein
Epitope	Unknown
Relevance	RPB1 is the largest and catalytic component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. It forms the polymerase active center together with the second largest subunit. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB1 is part of the core element with the central large cleft, the clamp element that moves to open and close the cleft and the jaws that are thought to grab the incoming DNA template. At the start of transcription, a single stranded DNA template strand of the promoter is positioned within the central active site cleft of Pol II. A bridging helix emanates from RPB1 and crosses the cleft near the catalytic site and is thought to promote translocation of Pol II by acting as a ratchet that moves the RNA-DNA hybrid through the active site by switching from straight to bent conformations at each step of nucleotide addition. During transcription elongation, Pol II moves on the template as the transcript elongates. Elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of Pol II largest subunit (RPB1), which serves as a platform for assembly of factors that regulate transcription initiation, elongation, termination and mRNA processing. Acts as a RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicate and transcriptase for the viral RNA circular genome.
Specificity	Yeast (Saccharomyces cerevisiae) RNA Pol II
Reported Reactivity	None
Reported Applications	Unknown

What's Happening at NeoClone Biotechnology You're probably wondering, "Now that BioLegend owns all your former catalog products, what the heck are you doing up there in Madison?" I'm glad you asked. We're still making great monoclonal antibodies, of course! NeoClone has been making custom murine antibodies via hybridoma technology for years. In fact, that's where our catalog came from in the first place! We decided that we needed to return our focus to custom projects, especially the really difficult targets that researchers had been bringing us all along. You know, the targets that other companies couldn't make due to problems with tolerance or toxicity or bizarre secondary structures. Then we decided to branch out into other methods of generating antibodies. We brought on new staff with years of experience in Antibody Phage Display and Camelid VHH antibodies. We've been upping our game in the Bioinformatics arena as well, giving us an edge in determining the best way to make YOUR antibody. Unlike other antibody development companies, we're not tied to one particular method. In the world of antibody development, one size does NOT fit all. So, you tell us what you want. We'll make sure we get it for you.